Skip to main content

Table 4 Univariate analysis of variance for mean tumor volume reduction

From: Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

   n Mean tumor volume reduction (%) ± SD P
After EC     
  Age (years)    
     -50 30 64.1 ± 25.9 0.1710
     51- 29 54.9 ± 25.4  
  Cancer stage    
     II 53 61.5 ± 25.1 0.0962
     III 5 55.7 ± 29.1  
     IV 2 21.9 ± 6.4  
  Tumor stage    
     T2 54 60.8 ± 25.3 0.3059
     T3 6 21.9 ± 6.4  
  Nodal status    
     N- 24 62.7 ± 24.9 0.4557
     N+ 36 57.6 ± 26.6  
  Subtype    
     Luminal A 37 58.8 ± 21.3 0.2923
     Luminal B 6 72.9 ± 9.4  
     HER2 11 50.4 ± 36.4  
     Basal-like 6 69.4 ± 37.0  
  DDR score    
     0 2 94.6 ± 7.6 0.0069
     1 15 57.3 ± 19.4  
     2 23 62.8 ± 22.9  
     3 12 61.1 ± 26.6  
     4 6 28.4 ± 28.1  
After EC-DOC     
  Age    
     -50 30 80.6 ± 23.9 0.0804
     51- 29 71.2 ± 15.7  
  Cancer stage    
     II 52 77.9 ± 19.8 0.1230
     III 5 64.3 ± 25.7  
     IV 2 54.7 ± 17.6  
  Tumor stage    
     T2 53 77.7 ± 19.7 0.0538
     T3 6 60.6 ± 24.7  
  Nodal status    
     N- 23 83.7 ± 14.3 0.0201
     N+ 36 71.0 ± 22.7  
  Subtype    
     Luminal A 36 77.9 ± 16.1 0.0789
     Luminal B 6 86.0 ± 9.5  
     HER2 11 62.4 ± 30.5  
     Basal-like 6 79.7 ± 24.8  
  DDR score    
     0 2 99.6 ± 0.6 0.0035
     1 14 77.2 ± 13.2  
     2 23 81.0 ± 14.7  
     3 12 70.7 ± 27.5  
     4 6 49.9 ± 22.0  
  1. DDR, DNA Damage Response; DOC, docetaxel; EC, epirubicin plus cyclophosphamide; HER, human epidermal growth factor receptor; SD, standard deviation.